| ALNYLAM ACT ALNYLAM PHARMACEUTICALS INC.
2333547 19 Jun 2024 | on 19 Jun 2024 | Class 042 Class 042 Computer & Software Services & Scientific Services DNA screening for scientific research purposes; DNA screening for forensic research purposes; DNA screening for genetic mutations for scientific research purposes; DNA screening for genetic mutations for forensic research purposes | | | ALNYLAMACT & DESIGN ALNYLAM PHARMACEUTICALS INC.
2333554 19 Jun 2024 | on 19 Jun 2024 | Class 042 Class 042 Computer & Software Services & Scientific Services DNA screening for scientific research purposes; DNA screening for forensic research purposes; DNA screening for genetic mutations for scientific research purposes; DNA screening for genetic mutations for forensic research purposes | | | ALNYLAM ALNYLAM PHARMACEUTICALS INC. A LEGAL ENTITY
1911136 24 Jul 2018 | on 30 Nov 2021 | Class 005 Class 005 Pharmaceutical Products Pharmaceutical preparations, namely, RNA therapeutics for use in the treatment of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection; Pharmaceuticals, biosimilars and biological preparations for medical and therapeutic purposes for use in the treatment of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection; pharmaceutical preparations, namely, RNA therapeutics | | | ALNYLAM ALNYLAM PHARMACEUTICALS INC.
(A DELAWARE CORPORATION)
1160197 25 Nov 2002 | on 31 Jan 2006 | Class 042 Class 042 Computer & Software Services & Scientific Services Scientific research, scientific research in the field of pharmaceuticals and medicine, medical laboratories. | |